#Ireland #Dublin #Autoimmune Diseases #Acthar Gel #Keenova

Keenova's Recent Manuscript Publication

Keenova Therapeutics plc has officially announced the publication of its new manuscript focusing on Acthar Gel, also known as repository corticotropin injection. This publication is significant as it delves into the application of this treatment for various severe autoimmune diseases. It was featured in the esteemed Journal of Comparative Effectiveness Research, which highlights rigorous studies in the healthcare field.

The manuscript presents findings from a retrospective, physician-reported, survey-based medical chart review. This study utilized real-world clinical data to assess various aspects like patient characteristics, treatment protocols, and physician observations of outcomes for patients diagnosed with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and dermatomyositis/polymyositis (DM/PM) who received Acthar Gel. This research not only provides clarity on the effectiveness of Acthar Gel but also aids clinicians in understanding its role in complex, often treatment-resistant cases.

According to George J. Wan, Vice President of Evidence, Value, and Outcomes at Keenova and the manuscript's senior author, there has been a lack of real-world evidence regarding Acthar Gel's use in cases of RA, SLE, or DM/PM. This new manuscript serves to address that gap, offering insight into how healthcare professionals are currently utilizing Acthar Gel in their treatment strategies.

Dr. Marek Honczarenko, Executive Vice President and Chief Scientific Officer at Keenova, emphasized the importance of access to effective therapies for patients grappling with severe autoimmune diseases. He stated, "Acthar Gel remains a viable option for those who have not found success with previous treatments, and we are dedicated to advancing the scientific knowledge surrounding this therapeutic approach."

Manuscript Details

The manuscript is titled “Acthar Gel treatment in patients with rheumatoid arthritis, systemic lupus erythematosus, or dermatomyositis/polymyositis: Analysis of physician-reported charts.” Key authors include Kyle Hayes, MS; Amit Patel, PhD; Priyanka P. Shanbhag, MS; Destri R. Evans, MBA; Mary Prince Panaccio, PhD; Johanna Purcell, PhD; and George J. Wan, PhD, MPH.

Background on Autoimmune Diseases

Understanding the conditions that Acthar Gel aims to treat is crucial for appreciating the manuscript's importance. Rheumatoid arthritis is a chronic autoimmune disorder characterized by the immune system wrongly attacking the joints, resulting in pain, stiffness, and potential joint damage. An estimated 1.5 million adults in the United States are affected by RA.

Systemic lupus erythematosus, commonly referred to as lupus, is another chronic inflammatory autoimmune condition. Symptoms can differ dramatically between patients and can impact various organs, including skin, joints, and kidneys. It is estimated that between 160,000 to 260,000 adults in the U.S. suffer from SLE.

Finally, dermatomyositis and polymyositis are rare diseases that primarily lead to muscle inflammation and weakness, with the skin condition often associated with the former. These conditions typically affect adults between 40 and 60 years old and are predominantly seen in women.

Implications for the Medical Community

The publication of this manuscript adds to the knowledge base regarding autoimmune disease treatments and reinforces the potential of Acthar Gel as a valuable asset in clinical practice. By providing thorough insights into the real-world effectiveness of this treatment, Keenova empowers healthcare professionals to make informed decisions for their patients.

Keenova Therapeutics, headquartered in Dublin, Ireland, is renowned for its focus on branded therapeutic solutions aimed at addressing rare and challenging health conditions. The company operates manufacturing facilities across several U.S. states, including Louisiana, New Jersey, New York, Pennsylvania, and Wisconsin, ensuring that they meet patient needs efficiently.

This publication is pivotal as it not only contributes to the academic discourse surrounding autoimmune treatments but also serves as a reminder of the necessity for continued research in developing effective therapies.

For more detailed information on the indications for and safety of Acthar Gel, it's encouraged to consult the comprehensive prescribing information available.